Azithromycin for COVID-19
Azithromycin for COVID-19
Highlights- Azithromycin reduces risk with high confidence for pooled analysis, low confidence for mortality, and very low confidence for cases.
- Early treatment is more effective than late treatment.
- Real-time updates and corrections with a consistent protocol for 227 treatments. Outcome specific analysis and combined evidence from all studies including treatment delay, a primary confounding factor.
Azithromycin COVID-19 studies
Azithromycin for COVID-19: meta-analysis results
Random-effects meta-analysis. Relative risk with 95% CI. * p < 0.05, ** p < 0.01, *** p < 0.001.
Azithromycin COVID-19 studies
Azithromycin COVID-19 mortality results
Azithromycin COVID-19 mechanical ventilation results
Azithromycin COVID-19 ICU results
Azithromycin COVID-19 hospitalization results
Azithromycin COVID-19 progression results
Azithromycin COVID-19 recovery results
Azithromycin COVID-19 case results
Azithromycin COVID-19 viral clearance results
Azithromycin COVID-19 peer reviewed studies
Azithromycin COVID-19 transmission results
COVID-19 RCT vs. observational results from 6,000+ studies
Azithromycin COVID-19 Randomized Controlled Trials
Azithromycin COVID-19 Randomized Controlled Trials after exclusions
Azithromycin COVID-19 RCT mortality results
Azithromycin COVID-19 RCT mortality results after exclusions
Azithromycin COVID-19 RCT hospitalization results
Azithromycin COVID-19 studies after exclusions
Media bias for low-cost COVID‑19 treatments
Media covered only 0.8% of studies showing significantly lower COVID-19 risk
Only 5 positive studies were covered
one each: budesonide, cannabidiol, fluvoxamine, HCQ, vitamin D
34 negative studies were covered
HCQ 12, ivermectin 6, lopinavir/ritonavir 4, azithromycin 3, vitamin D 3, fluvoxamine 2, one each: ibuprofen, metformin, vitamin C, zinc
Media was 3.8× more likely to cover positive studies
19 positive studies were covered
paxlovid 5, remdesivir 3, casirivimab/imdevimab 2, convalescent plasma 2, molnupiravir 2, one each: antiandrogens, peginterferon lambda, sargramostim, tixagevimab/cilgavimab, tocilizumab
Only 6 negative studies were covered
remdesivir 3, one each: bamlanivimab/etesevimab, bebtelovimab, sotrovimab
National treatment protocols
Protocols varied widely
Most widely used early treatments selected by the most populous countries. Official protocols varied widely. Treatments only expected to be helpful for late-stage patients are excluded. low-cost, high-profit, and increased risk.
Full matrix and analysis →| Evidence | Official Acknowledgment | Approx. Delay | |
|---|---|---|---|
| Citrus Fruit (vitamin C) for Scurvy (effectiveness) | 1747: James Lind conducted one of the first-ever controlled clinical trials, proving that oranges and lemons cured scurvy in sailors. | 1795: The British Royal Navy finally made a daily ration of lemon juice a standard issue for all its sailors, effectively eliminating the disease. | 48 years |
| Handwashing (lower mortality) | 1847: Dr. Ignaz Semmelweis provided conclusive proof that having doctors wash their hands with a chlorine solution before delivering babies reduced maternal mortality rates from over 18% to around 1%. | ~1870s: Semmelweis's findings were rejected and he was ridiculed. His work was only validated decades later (after his death). | ~20+ years |
| Helicobacter pylori (bacteria causes ulcers) | 1982-1984: Marshall and Warren discovered that Helicobacter pylori bacteria causes ulcers, confirmed via direct exposure. Officials maintained that ulcers were caused by stress and spicy food. | 1994: The US NIH released a consensus statement officially recommending antibiotics as the standard treatment for peptic ulcers, overturning decades of acid-suppression therapy. | ~12 years |
| Asbestos (causes asbestosis & cancer) | 1924: The British Medical Journal published the first case study of a death from "asbestosis." By 1918, U.S. insurance companies had stopped selling life insurance to asbestos workers. | 1971 (US): The Occupational Safety and Health Administration (OSHA) was formed and began regulating asbestos as a carcinogen, setting the first federal workplace safety standards for it. | ~47 years |
| Leaded Gasoline (neurotoxicity) | ~1924: Dangers of low-level lead exposure were known. Experts like Alice Hamilton warned the U.S. Surgeon General that adding lead to gasoline would cause widespread public poisoning. | 1973 (US): The Environmental Protection Agency (EPA) ordered the first phasedown of lead in gasoline, following the Clean Air Act of 1970. A full ban for on-road vehicles took effect in 1996. | ~49 years |
| Harms of Smoking (causes lung cancer) | 1939: Franz Müller (Germany) published the first case-control epidemiological study strongly linking tobacco smoking to lung cancer. This was followed by major U.S. & U.K. studies in the 1950s. | 1964 (US): The U.S. Surgeon General's report, "Smoking and Health," was released. It was the first U.S. government report to definitively link smoking to lung cancer and heart disease. | 25 years |
Early treatment is more effective: baloxavir marboxil
| Tissue and cell coverage | Different compounds have different tissue penetration profiles and efficacy across cell types |
| Variant coverage | Compounds with different viral resistance profiles |
| Intra/extracellular | Disabling and removing intracellular and extracellular viral particles |
| Resistance | Minimizing persistence and emergence of resistant variants |
| Genetics | Robustness against individual variations in efficacy based on genetics |
| Lower doses | Potentially lower doses of individual agents, reducing toxicity |
| Viral and host-directed | Antivirals targeting viral and host proteins |
| Immune system function | Supporting or enhancing natural immune system function |
| Disease phases | Addressing multiple disease phases (viral replication, inflammation, secondary complications) |
reduces riskAzithromycin
increases risk →
reduces riskAzithromycin
increases risk →
reduces riskAzithromycin
increases risk →
reduces riskAzithromycin
increases risk →
| Treatment patients | Duration | Results delay | |
|---|---|---|---|
| HCQ216 | 413 | 2 months | Over 5 years216 |
| Azithromycin172 | 540 | 6 months | 56 days217 |
| Budesonide218 | 1,073 | 4 months | 12 days219 |
| Doxycycline220 | 780 | 5 months | 42 days217 |
| Colchicine221 | 156 | 3 months | 120 days222 |
| Ivermectin41 | 2,157 | 14 months | 600 days (810 days from ~1,000 per arm enrollment) |
| Favipiravir223 | ~2,250 | 15 months | 780 days (1,000 days from ~1,000 per arm enrollment) |
reduces riskAzithromycin
increases risk →
Authors note: "the trial cannot definitively rule out either a substantial benefit of the trial drugs or a substantial harm", sample sizes are too small.
The paper uses the terms mild and moderate, however all patients had serious enough disease to be hospitalized, and 14% were actually randomized in the ICU.
The trial had significant protocol deviations and unusually low medication adherence.
Authors note: "our aim was to exclude patients already receiving longer and potentially therapeutic doses of the study treatments" in explanation for why the study protocol was changed to exclude patients with previous use of the medications >24hrs. Analyzing these patients rather than excluding them may have revealed effectiveness with early use as shown in other studies.
The trial initially required enrollment within 48 hours of admission and was changed to remove this requirement, this change is likely to reduce effectiveness because enrollment was moved later, compared to the time the disease became serious enough for hospitalization. Total HCQ dosage 5.6g.
A correction for 17 errors has been published224.
reduces riskAzithromycin
increases risk →
reduces riskAzithromycin
increases risk →
reduces riskAzithromycin
increases risk →
reduces riskAzithromycin
increases risk →
reduces riskAzithromycin
increases risk →
reduces riskAzithromycin
increases risk →
Patients received 8g of HCQ over 10 days, approaching the high levels used in the RECOVERY trial (9.2g over 10 days), showing significantly more adverse events than typical trials. 50% of patients were on mechanical ventilation at baseline.
More than the increase in mortality at day 29 occurred on day 0, and more than 3x the increase occurred by day 2.
reduces riskAzithromycin
increases risk →
reduces riskAzithromycin
increases risk →
reduces riskAzithromycin
increases risk →
reduces riskAzithromycin
increases risk →
7 vs. 3 hospitalizations occurred by day 1 in the treatment vs. control groups in this open label trial (Figure 2).
reduces riskAzithromycin
increases risk →
reduces riskAzithromycin
increases risk →
reduces riskAzithromycin
increases risk →
reduces riskAzithromycin
increases risk →
reduces riskAzithromycin
increases risk →
reduces riskAzithromycin
increases risk →
reduces riskAzithromycin
increases risk →
reduces riskAzithromycin
increases risk →
Confounding by indication is likely to be significant for many medications. Authors adjustments have very limited severity information (admission type refers to ward vs. ER department on initial arrival). We can estimate the impact of confounding from typical usage patterns, the prescription frequency, and attenuation or increase of risk for ICU vs. all patients.
reduces riskAzithromycin
increases risk →
reduces riskAzithromycin
increases risk →
Authors note that the results are not applicable to higher risk patients, that positive PCR may simply reflect detection of inactive (non-infectious) viral remnants, that an alternative dosage regimen may be more effective, and that medication adherence was unknown.
HCQ dosing was 600mg/day for 1 week, therapeutic levels may not be reached for several days. There were no deaths or serious adverse events.
Viral load was already very high at baseline.
reduces riskAzithromycin
increases risk →
reduces riskAzithromycin
increases risk →
reduces riskAzithromycin
increases risk →
reduces riskAzithromycin
increases risk →
reduces riskAzithromycin
increases risk →
reduces riskAzithromycin
increases risk →

| Lounnas, 2/29/2024, retrospective, France, peer-reviewed, 6 authors, study period March 2020 - December 2021. | risk of death/ICU, 27.3% lower, OR 0.73, p < 0.001, adjusted per study, propensity score matching, multivariable, RR approximated with OR. |
| Omrani, 11/20/2020, Double Blind Randomized Controlled Trial, placebo-controlled, Qatar, peer-reviewed, 19 authors, study period 13 April, 2020 - 1 August, 2020, Q-PROTECT trial. | risk of hospitalization, 33.3% higher, RR 1.33, p = 1.00, treatment 4 of 152 (2.6%), control 3 of 152 (2.0%), HCQ+AZ vs. HCQ. |
| progression to pneumonia, 66.7% lower, RR 0.33, p = 0.62, treatment 1 of 152 (0.7%), control 3 of 152 (2.0%), NNT 76, HCQ+AZ vs. HCQ. | |
| risk of symptomatic at day 21, 100% higher, RR 2.00, p = 0.50, treatment 6 of 152 (3.9%), control 3 of 152 (2.0%), HCQ+AZ vs. HCQ. | |
| relative improvement in Ct, 4.2% worse, RR 1.04, p = 0.63, treatment 152, control 152, HCQ+AZ vs. HCQ, day 6. | |
| Rashad, 8/11/2021, Randomized Controlled Trial, Egypt, peer-reviewed, 10 authors, study period May 2020 - September 2020, trial NCT04622891 (history). | risk of no improvement, 25.6% lower, RR 0.74, p = 0.09, treatment 37 of 107 (34.6%), control 46 of 99 (46.5%), NNT 8.4. |
| time to viral-, 34.1% lower, relative time 0.66, p < 0.001, treatment mean 8.7 (±2.8) n=107, control mean 13.2 (±4.2) n=99. |
| AlQadheeb, 5/10/2023, retrospective, Saudi Arabia, peer-reviewed, mean age 55.8, 9 authors, study period March 2020 - August 2021. | risk of death, 22.2% higher, RR 1.22, p = 0.08, treatment 467 of 775 (60.3%), control 36 of 73 (49.3%). |
| Alqahtani, 3/12/2025, retrospective, Saudi Arabia, peer-reviewed, mean age 56.7, 15 authors, study period 13 March, 2020 - 13 September, 2020. | risk of death, 9.0% lower, OR 0.91, p = 0.85, treatment 159, control 26, RR approximated with OR. |
| Atefi, 11/20/2023, retrospective, Iran, peer-reviewed, 10 authors, trial IRCT20200623047897N1. | risk of death, 85.1% lower, RR 0.15, p = 0.31, treatment 0 of 18 (0.0%), control 4 of 42 (9.5%), NNT 10, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm). |
| Butler, 3/31/2021, Randomized Controlled Trial, United Kingdom, peer-reviewed, 18 authors, study period 22 May, 2020 - 30 November, 2020, average treatment delay 6.0 days, trial ISRCTN86534580 (PRINCIPLE). | risk of mechanical ventilation, 49.6% lower, RR 0.50, p = 0.47, treatment 2 of 496 (0.4%), control 5 of 625 (0.8%), NNT 252. |
| risk of ICU admission, 24.2% lower, RR 0.76, p = 1.00, treatment 3 of 495 (0.6%), control 5 of 625 (0.8%), NNT 516. | |
| risk of oxygen therapy, 16.2% lower, RR 0.84, p = 0.69, treatment 10 of 497 (2.0%), control 15 of 625 (2.4%), NNT 258. | |
| risk of hospitalization, 8.5% lower, RR 0.91, p = 0.87, treatment 16 of 500 (3.2%), control 22 of 629 (3.5%), NNT 336, concurrent randomization, day 28, Table S2. | |
| risk of no recovery, 7.4% lower, HR 0.93, p = 0.23, treatment 500, control 823, inverted to make HR<1 favor treatment, first reported recovery. | |
| Cavalcanti, 7/23/2020, Randomized Controlled Trial, Brazil, peer-reviewed, baseline oxygen required 41.8%, 35 authors, study period 29 March, 2020 - 18 May, 2020, trial NCT04322123 (history) (COALITION I). | risk of death, 57.0% lower, HR 0.43, p = 0.17, treatment 5 of 172 (2.9%), control 7 of 159 (4.4%), adjusted per study, HCQ+AZ vs. HCQ. |
| risk of death, 44.5% lower, RR 0.55, p = 0.49, treatment 3 of 172 (1.7%), control 5 of 159 (3.1%), NNT 71, HCQ+AZ vs. HCQ, day 15. | |
| risk of mechanical ventilation, 54.0% higher, HR 1.54, p = 0.28, treatment 19 of 172 (11.0%), control 12 of 159 (7.5%), adjusted per study, HCQ+AZ vs. HCQ. | |
| risk of 7-point scale, 18.0% lower, OR 0.82, p = 0.49, treatment 172, control 159, adjusted per study, HCQ+AZ vs. HCQ, RR approximated with OR. | |
| Corradini, 4/24/2021, retrospective, Italy, peer-reviewed, 60 authors. | risk of death, 12.0% higher, OR 1.12, p = 0.38, treatment 222, control 1,479, adjusted per study, Table S6, all patients, multivariable, RR approximated with OR. |
| Dinoi, 2/20/2025, retrospective, Italy, peer-reviewed, 11 authors, study period 17 March, 2020 - 15 June, 2021. | risk of death, 27.7% lower, OR 0.72, p = 0.08, treatment 87 of 247 (35.2%) cases, 106 of 247 (42.9%) controls, NNT 12, case control OR. |
| Donida, 1/31/2024, retrospective, Italy, peer-reviewed, 4 authors, study period 21 February, 2020 - 31 May, 2020. | risk of death, 7.0% lower, HR 0.93, p = 0.79, treatment 180 of 548 (32.8%), control 101 of 175 (57.7%), NNT 4.0, adjusted per study, multivariable, Cox proportional hazards. |
| Frontera, 10/26/2020, retrospective, USA, preprint, median age 64.0, 14 authors, excluded in exclusion analyses: substantial confounding by time likely due to declining usage over the early stages of the pandemic when overall treatment protocols improved dramatically. | risk of death, 22.0% higher, HR 1.22, p = 0.07, treatment 2,014, control 1,459, adjusted per study. |
| Furtado, 9/4/2020, Randomized Controlled Trial, Brazil, peer-reviewed, 33 authors, average treatment delay 8.0 days, trial NCT04321278 (history) (COALITION II), excluded in exclusion analyses: very late stage patients. | risk of death, 8.0% higher, HR 1.08, p = 0.63, treatment 90 of 214 (42.1%), control 73 of 183 (39.9%), day 29. |
| risk of death, 2.6% higher, RR 1.03, p = 0.91, treatment 66 of 214 (30.8%), control 55 of 183 (30.1%), day 15. | |
| 6 point scale, 30.1% lower, OR 0.70, p = 0.08, treatment 214, control 183, inverted to make OR<1 favor treatment, day 29, RR approximated with OR. | |
| 6 point scale, 26.5% lower, OR 0.74, p = 0.10, treatment 214, control 183, inverted to make OR<1 favor treatment, day 15, primary outcome, RR approximated with OR. | |
| Gadhiya, 4/8/2021, retrospective, USA, peer-reviewed, 4 authors, excluded in exclusion analyses: substantial unadjusted confounding by indication likely. | risk of death, 72.8% higher, RR 1.73, p = 0.15, treatment 43 of 182 (23.6%), control 12 of 101 (11.9%), adjusted per study, odds ratio converted to relative risk, multivariate logistic regression. |
| Ghanei, 9/15/2021, Randomized Controlled Trial, Iran, peer-reviewed, 18 authors, study period 13 April, 2020 - 9 August, 2020. | risk of death, 18.9% lower, RR 0.81, p = 0.79, treatment 10 of 226 (4.4%), control 6 of 110 (5.5%), NNT 97, azithromycin groups vs. lopinavir/ritonavir. |
| risk of mechanical ventilation, 51.3% lower, RR 0.49, p = 0.40, treatment 3 of 226 (1.3%), control 3 of 110 (2.7%), NNT 71, azithromycin groups vs. lopinavir/ritonavir. | |
| risk of ICU admission, 23.5% lower, RR 0.76, p = 0.61, treatment 11 of 226 (4.9%), control 7 of 110 (6.4%), NNT 67, azithromycin groups vs. lopinavir/ritonavir. | |
| Gyselinck, 1/27/2022, Randomized Controlled Trial, Belgium, peer-reviewed, mean age 62.0, 23 authors, study period 24 April, 2020 - 17 December, 2021, average treatment delay 7.0 days, trial EudraCT-2020-001614-38A. | risk of death, 10.9% higher, HR 1.11, p = 0.87, treatment 119, control 64, Kaplan-Meier. |
| risk of mechanical ventilation, 26.2% lower, HR 0.74, p = 0.50, treatment 119, control 64. | |
| risk of ICU admission, 6.6% higher, HR 1.07, p = 0.85, treatment 119, control 64. | |
| risk of no recovery, 2.2% lower, HR 0.98, p = 0.89, treatment 119, control 64, inverted to make HR<1 favor treatment. | |
| Hinks, 10/31/2021, Randomized Controlled Trial, United Kingdom, peer-reviewed, mean age 45.0, 22 authors, study period 3 June, 2020 - 29 January, 2021, average treatment delay 6.02 days, trial NCT04381962 (history) (ATOMIC2). | risk of death, 1.4% higher, RR 1.01, p = 1.00, treatment 1 of 145 (0.7%), control 1 of 147 (0.7%). |
| risk of death/hospitalization, 1.0% lower, HR 0.99, p = 0.99, treatment 15 of 145 (10.3%), control 17 of 147 (11.6%), NNT 82, Cox proportional hazards, model 3. | |
| risk of death/hospitalization, 8.0% lower, RR 0.92, p = 0.82, treatment 15 of 145 (10.3%), control 17 of 147 (11.6%), NNT 82, adjusted per study, odds ratio converted to relative risk, model 3. | |
| progression to pneumonia, 80.3% lower, RR 0.20, p = 0.24, treatment 0 of 119 (0.0%), control 2 of 114 (1.8%), NNT 57, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm). | |
| Horby, 2/28/2021, Randomized Controlled Trial, United Kingdom, peer-reviewed, mean age 65.0, 34 authors, study period 7 April, 2020 - 27 November, 2020, average treatment delay 8.0 days, trial NCT04381936 (history) (RECOVERY), excluded in exclusion analyses: very late stage patients. | risk of death, 3.0% lower, RR 0.97, p = 0.50, treatment 561 of 2,582 (21.7%), control 1,162 of 5,181 (22.4%), NNT 143, day 28, primary outcome. |
| risk of mechanical ventilation, 8.0% lower, RR 0.92, p = 0.29, treatment 211 of 2,430 (8.7%), control 461 of 4,881 (9.4%), NNT 131. | |
| Kayembe, 5/7/2021, retrospective, Democratic Republic of Congo, peer-reviewed, 9 authors, study period 10 March, 2020 - 31 August, 2020, this trial uses multiple treatments in the treatment arm (combined with HCQ) - results of individual treatments may vary. | risk of death, 47.4% lower, HR 0.53, p = 0.03, treatment 1,100, control 135, inverted to make HR<1 favor treatment, 988 included for analysis, Cox proportional hazards, day 15. |
| Kokturk, 4/28/2021, retrospective, database analysis, Turkey, peer-reviewed, 68 authors. | risk of death, 50.5% higher, RR 1.50, p = 0.47, treatment 34 of 738 (4.6%), control 33 of 762 (4.3%), adjusted per study, odds ratio converted to relative risk. |
| Kuderer, 5/28/2020, retrospective, USA, peer-reviewed, 73 authors, excluded in exclusion analyses: substantial unadjusted confounding by indication likely. | risk of death, 26.8% higher, RR 1.27, p = 0.46, treatment 12 of 93 (12.9%), control 41 of 486 (8.4%), odds ratio converted to relative risk, AZ. |
| risk of death, 152.0% higher, RR 2.52, p < 0.001, treatment 45 of 181 (24.9%), control 41 of 486 (8.4%), odds ratio converted to relative risk, HCQ+AZ. | |
| Mehrizi, 12/18/2023, retrospective, Iran, peer-reviewed, 10 authors, study period 1 February, 2020 - 20 March, 2022. | risk of death, 32.0% lower, OR 0.68, p < 0.001, RR approximated with OR. |
| Oldenburg, 8/10/2021, Double Blind Randomized Controlled Trial, placebo-controlled, USA, peer-reviewed, median age 43.0, 15 authors, study period 22 May, 2020 - 16 March, 2021, average treatment delay 7.0 days, trial NCT04332107 (history) (ACTION). | risk of hospitalization, 788.0% higher, RR 8.88, p = 0.16, treatment 5 of 125 (4.0%), control 0 of 72 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), day 21. |
| ED visit, 418.4% higher, RR 5.18, p = 0.01, treatment 18 of 125 (14.4%), control 2 of 72 (2.8%), ED visit or urgent care, day 21. | |
| risk of no recovery, 0.8% lower, RR 0.99, p = 1.00, treatment 65 of 131 (49.6%), control 35 of 70 (50.0%), NNT 262, day 21. | |
| risk of transmission, 12.1% lower, RR 0.88, p = 0.66, treatment 33 of 522 (6.3%), control 20 of 278 (7.2%), NNT 115, day 21. | |
| Sekhavati, 10/31/2020, Randomized Controlled Trial, Iran, peer-reviewed, 18 authors, study period 24 April, 2020 - 8 May, 2020. | risk of death, 66.9% lower, RR 0.33, p = 0.50, treatment 0 of 56 (0.0%), control 1 of 55 (1.8%), NNT 55, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm). |
| risk of mechanical ventilation, 85.8% lower, RR 0.14, p = 0.12, treatment 0 of 56 (0.0%), control 3 of 55 (5.5%), NNT 18, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm). | |
| risk of ICU admission, 71.9% lower, RR 0.28, p = 0.09, treatment 2 of 56 (3.6%), control 7 of 55 (12.7%), NNT 11. | |
| hospitalization time, 22.7% lower, relative time 0.77, p = 0.02, treatment 56, control 55. | |
| Traore, 1/17/2025, retrospective, Mali, peer-reviewed, median age 43.0, 14 authors, study period 27 March, 2020 - 30 June, 2022. | risk of death, 69.0% lower, HR 0.31, p = 0.04, adjusted per study, multivariable. |
| Yeramaneni, 2/28/2021, retrospective, USA, peer-reviewed, 6 authors, study period 11 February, 2020 - 8 May, 2020. | risk of death, 7.0% lower, OR 0.93, p = 0.84, treatment 4,003, control 3,155, adjusted per study, multivariable, day 30, RR approximated with OR. |
| Yilgwan, 5/11/2023, retrospective, Nigeria, peer-reviewed, 12 authors, study period 25 February, 2020 - 30 August, 2021. | risk of death, 67.0% lower, OR 0.33, p < 0.001, treatment 1,619, control 1,843, RR approximated with OR. |
| Dugot, 3/15/2023, retrospective, Israel, peer-reviewed, 7 authors, study period 1 March, 2020 - 31 December, 2020. | risk of case, 11.8% lower, OR 0.88, p < 0.001, treatment 1,297 of 31,260 (4.1%) cases, 5,919 of 125,039 (4.7%) controls, NNT 47, adjusted per study, case control OR, multivariable. |
| Huh, 12/19/2020, retrospective, database analysis, South Korea, peer-reviewed, 8 authors. | risk of progression, 53.6% higher, RR 1.54, p = 0.33, treatment 3 of 6 (50.0%), control 875 of 2,799 (31.3%), adjusted per study, odds ratio converted to relative risk, multivariable. |
| risk of case, 42.0% lower, OR 0.58, p = 0.10, treatment 11 of 7,341 (0.1%) cases, 103 of 36,705 (0.3%) controls, NNT 14, adjusted per study, case control OR, multivariable. | |
| Loucera, 8/16/2022, retrospective, Spain, peer-reviewed, 8 authors, study period January 2020 - November 2020. | risk of death, 15.0% lower, HR 0.85, p = 0.005, treatment 2,465, control 13,503, Cox proportional hazards, day 30. |
| Piñana, 8/25/2020, retrospective, Spain, peer-reviewed, median age 64.0, 46 authors, study period 1 March, 2020 - 15 May, 2020. | risk of death, 58.0% lower, OR 0.42, p = 0.02, adjusted per study, multivariable, RR approximated with OR. |

